|
is a biopharmaceutical company that discovers
and develops for commercialization antibodies
and other genetically-engineered protein products
to treat immunological and inflammatory disorders,
cancer and infectious diseases. The Company’s
products are presently in various stages of development
and most are subject to regulatory approval before
they can be introduced commercially. The Company
receives royalties from Genentech, Inc. (“Genentech”)
on two approved products, RAPTIVA ® , for
the treatment of moderate-to-severe plaque psoriasis,
and LUCENTIS™, for the treatment of neovascular
(wet) age-related macular degeneration. XOMA’s
pipeline includes both proprietary products and
collaborative programs at various stages of preclinical
and clinical development.
XOMA|
about
| contact
|
Investor Relations
|